Biological response modifiers (BRM) are a new approach of cancer treatment
The guidelines for their evaluation are comparable to those used for evalua
ting conventional anticancer treatments However it is more difficult to ass
ess their efficacy and toxicity because of their own properties and of the
characteristics of underlying diseases. The objectives of studying BRM effi
cacy are the following: 1- to confirm the pharmacodynamic effect observed i
n experimental models 2- to assess the benefit for the patient Phase IT stu
dies can occasionally be performed in healthy volunteers. Efficacy criteria
are objective response rate, progression free survival overall survival or
, for hematopoietic growth factors, more specific criteria. In randomized p
hase III studies patients in the control arm can be observed without treatm
ent or receive a placebo or a standard treatment. Rr regards toxicity, side
effects specifically related to the use of BRM are the synthesis of cytoki
nes, the stimulation of immune system, the stimulation of tumor growth, the
synthesis of anti-mouse of anti-BRM antobodies.